Choose among a broad range of powerful transfection reagents specifically developed to enable you to reach the desired level of protein expression in a wide range of adherent and suspension mammalian cell types, primary and cell lines. Transfection reagents are ready-to-use with a pre-optimized protocol to ensure high transfection efficiency while preserving cell viability and morphology.
Gene and Cell Therapy rely on the use of modified viruses as vectors to transfer genes into cells that they are able to infect. Modified viruses used as vectors are derived from adeno-associated viruses (AAV), lentiviruses, retroviruses and adenoviruses. These viral vectors first need to be produced in mammalian cells. Production of viral vectors is dependent on efficient transfection of one to several plasmid DNA containing the necessary viral genome to produce recombinant viral particles.
Protein production consists in overexpressing recombinant proteins (eg. antibodies) and peptides mainly in mammalian cell lines HEK-293, CHO and derivatives. Transfection of plasmid DNA encoding for the protein of interest in a given cell line can be used for both transient and stable protein production. Transient protein expression allows generation of high protein amounts in a short amount of time and can offer a reliable alternative to production of stable cell lines for proof of concept studies and tools validation. Polyplus-transfection has developed a range of products specifically designed for protein production in CHO and HEK-293 cells grown in suspension in synthetic serum-free media.
Non-viral in vivo delivery reagents are the most powerful alternative to viral vectors for nucleic acid delivery. They offer substantial advantages in terms of reliability, safety and costs for nucleic-acid based therapies. Different quality grades of in vivo transfection reagents are available for proof concept studies, preclinical studies and clinical trials.
Polyplus is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services. Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help customers (or the industry) optimize process economics while meeting strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia.
Search in our Transfection Database
Search in the publication database with Polyplus transfection reagents or for transfection conditions
(over 4000 publications, 1000 cell lines and primary cells available).
Boston Convention and Exhibition Center Boston, MA
Edinburgh International Conference Centre